Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drug
Boehringer Ingelheim reported positive outcomes from the Beamion LUNG-1 trial, assessing zongertinib for treating NSCLC with HER2 mutations. The trial met its primary endpoint, showing a 66.7% objective response rate and a tolerable safety profile, with no treatment-related deaths.
Highlighted Terms
Related News
Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drug
Boehringer Ingelheim reported positive outcomes from the Beamion LUNG-1 trial, assessing zongertinib for treating NSCLC with HER2 mutations. The trial met its primary endpoint, showing a 66.7% objective response rate and a tolerable safety profile, with no treatment-related deaths.